Potential for pregabalin abuse or diversion after past drug-seeking behavior

Journal of the American Osteopathic Association

Volumn 110, Issue 10, 2010, Pages 605-607

  Filipetto, Frank A ^a   Zipp, Christopher P ^a   Coren, Joshua S ^a  

^a UMDNJ School of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; NARCOTIC ANALGESIC AGENT; PREGABALIN;

ADDICTION; ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; PAIN; RISK FACTOR;

ADULT; ANALGESICS; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; PAIN; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 79952279452     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. US Department of Justice, Office of the Inspector General, Evaluation and Inspections Division. Follow-Up Review of the Drug Enforcement Administration's Efforts to Control the Diversion of Controlled Pharmaceuticals. US Department of Justice; 2006. http://www.justice.gov/oig//reports/DEA/e0604/back.htm. Accessed October 1, 2010.
2. Office of Applied Studies, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services. Results from the 2007 National Survey on Drug Use and Health. National Findings. Rockville, MD: US Department of Health and Human Services; 2008. DHHS Publication No. SMA 08-4343. NSDUH Series: H-34.
3. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13:401-435.
4. The Controlled Substances Act. US Drug Enforcement Administration Web site. http://www.usdoj.gov/dea/pubs/abuse/1-csa.htm. Accessed September 26, 2009.
5. Highlights of prescribing information. In: Physicians' Desk Reference. 63rd ed. Montvale, NJ: Thomson Reuters; 2009:2527-2534.
6. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into Schedule V. Final rule. Fed Regist. 2005;70(144):43633-43635.
7. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64(14):1575-1582.
8. Lyrica [package insert]. Sandwich, Kent, UK: Pfizer Ltd; 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf. Accessed October 1, 2010.
9. Oulis P, Masdrakis VG, Karakatsanis NA, et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol. 2008;23(2):110-112.
10. Strawn JR, Dowling BP, Geracioti TD Jr. Pregabalin treatment of posttraumatic stress disorder. J Clin Psychopharmacol. 2008;28(5):596-597.
11. Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41(4):399-406.
12. Martinotti G, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther. 2008;25(6):608-618.
13. van Seventer R, Flemming WB, Toth C, et al. Pregabalin is effective in the treatment of posttraumatic peripheral neuropathic pain. Poster presented at: American Academy of Neurology 61st Annual Meeting; April 29, 2009; Seattle, WA. P05.056.
14. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 2007;7(7):769-781.
15. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into Schedule V. Proposed rule. Federal Regist. 2005;70(92):25502-25505.
16. Chalabianloo F, Schiott J. Pregabalin and abuse potential [review] [in Norwegian]. Tidsskr Nor Laegeforen. 2009;129(3):186-187.
17. Lipman AG, Jackson KC II. Opioid pharmacotherapy. In: Warfield CA, Bajwa ZA. Principles & Practice of Pain Medicine. 2nd ed. New York, NY: McGraw-Hill; 2004:595.
18. Wootton RJ, Caudill-Slosberg MA, Frank JB. Psycotherapeutic management of chronic pain. In: Warfield CA, Bajwa ZA. Principles & Practice of Pain Medicine. 2nd ed. New York, NY: McGraw-Hill; 2004:158-159.
19. Office of Diversion Control, Drug Enforcement Administration, US Department of Justice. Drugs and chemicals of concern. US Drug Enforcement Administration Web site. http://www.deadiversion.usdoj.gov/drugs_concern/index.html. Accessed September 26, 2009.
20. Office of Diversion Control, Drug Enforcement Administration, US Department of Justice. Rules - 2010. US Drug Enforcement Administration Web site. http://www.deadiversion.usdoj.gov/fed_regs/rules/2010/fr0326.htm. Published March 21, 2010. Accessed April 20, 2010